Bookmark and Share

Richard B. Horenstein

Richard B. Horenstein M.D., J.D.

Academic Title: Associate Professor
Primary Appointment: Medicine
Location: HH 494
Phone: (410) 706-0154
Fax: (410) 706-1622

Research Interests:

Genetics of Lipid Disorders (Dyslipidemia); Genetics of Type 2 Diabetes and Obesity; Management of Type 2 Diabetes, Thyroid Disorders, and Thyroid Cancer; Cardiovascular Disease Prevention.


Search My Publications in Pub Med


Horenstein R, Smith D, Mosca L.  Cholesterol predicts stoke mortality in the Women’s Pooling Project. Stroke 33:1863-1868 (7/02).
Gong D, Yang R, Munir K, Horenstein R, Shuldiner A.  New progress in adipocytokine research. Curr Opin Endocrinol and Diabetes 10(2):115-121 (4/03).
Armand R, Cappola A, Horenstein R, Drachenberg C, Sasano H, Papadimitriou J.  Adrenal cortical adenoma with excess black pigment deposition, combined with myelolipoma and clinical Cushing’s syndrome. Int J Surg Pathol 12:57-61 (1/04).
Horenstein R, Shuldiner A.  Genetics of Diabetes. Rev Endocrine and Metabol Disord 5:25-36 (3/04).
Horenstein, R, Shuldiner A. Does bariatric surgery reduce obesity-related co-morbidities? Curr Diabetes Reports 5:2 (4/05).
Yang R-Z, Lee M-J, Hu H, Pollin T, Ryan A, Nicklas B, Snitker S, Horenstein R, Hull K, Goldberg N, Goldberg A, Shuldiner A, Fried S, Gong D-W. Acute-phase Serum Amyloid A is a Pro-inflammatory Adipokine in Humans and a Potential Link Between Obesity and its Metabolic Complications. PloS-Medicine 3(6): e287 (2006).

Pollin T, Damcott C, Shen H, Ott S, Shelton J, Horenstein R, Post W, McLenithan J, Bielak L, Peyser P, Mitchell B, Miller M, O’Connell J, Shuldiner A. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection. Science 2008;322:1702-1705.

Bielak L, Horenstein R, Ryan K, Sheedy P, Rumberger J, Tanner K, Post W, Mitchell B, Shuldiner A, Peyser P. Circulating CD34+ Cell Count is Associated with Extent of Subclinical Atherosclerosis in Asymptomatic Amish Men, Independent of 10-Year Framingham Risk. Clinical Medicine: Cardiology 2009; 3:53-60.

Shuldiner A, O’Connell J, Bliden K, Gandhi A, Ryan K, Horenstein R, Damcott C, Pakyz R, Gibson Q, Pollin T, Post W, Parsa A, Mitchell B, Faraday N, Herzog W, Gurbel P. Cytochrome p450 2C19 Genotype is a Major Determinant of the Anti-Platelet Effect and Clinical Efficacy of Clopidogrel Therapy. JAMA 2009;302:849-857.